These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 3157705)

  • 1. The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin.
    Brittain DC; Scully BE; McElrath MJ; Steinman R; Labthavikul P; Neu HC
    J Clin Pharmacol; 1985 Mar; 25(2):82-8. PubMed ID: 3157705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacology of orally administered ciprofloxacin.
    Brittain DC; Scully BE; McElrath MJ; Steinman R; Labthavikul P; Neu HC
    Drugs Exp Clin Res; 1985; 11(5):339-41. PubMed ID: 2941262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose.
    Well M; Naber KG; Kinzig-Schippers M; Sörgel F
    Int J Antimicrob Agents; 1998 Apr; 10(1):31-8. PubMed ID: 9624541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bactericidal activity of ciprofloxacin in serum and urine against Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Staphylococcus aureus and Streptococcus faecalis.
    Lagast H; Husson M; Klastersky J
    J Antimicrob Chemother; 1985 Sep; 16(3):341-7. PubMed ID: 2932416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose.
    Boy D; Well M; Kinzig-Schippers M; Sörgel F; Ankel-Fuchs D; Naber KG
    Int J Antimicrob Agents; 2004 Mar; 23 Suppl 1():S6-16. PubMed ID: 15037323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative "in vitro" activity of ciprofloxacin (Bay o9867) and other antimicrobial agents against urinary bacterial isolates.
    Piccolomini R; Ravagnan G
    Chemioterapia; 1986 Aug; 5(4):249-56. PubMed ID: 3769047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1996)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Shimizu Y; Terai T; Inoue H; Nakadate T; Ito C; Yoshida T; Ohno I; Tanno Y; Arakawa M; Igarashi K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Nakata K; Nakatani T; Inagawa H; Kusano N
    Jpn J Antibiot; 1998 Jul; 51(7):437-74. PubMed ID: 9755430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary bactericidal activity of oral antibiotics against common urinary tract pathogens in an ex vivo model.
    Bedenic B; Topic M; Budimir A; Bubonja M
    Chemotherapy; 2006; 52(6):293-7. PubMed ID: 17008781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-antibiotic suppressive effect of ciprofloxacin against gram-positive and gram-negative bacteria.
    Chin NX; Neu HC
    Am J Med; 1987 Apr; 82(4A):58-62. PubMed ID: 3578330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative crossover assessment of serum bactericidal activity and pharmacokinetics of ciprofloxacin and ofloxacin.
    Echols R; Weinstein MP; O'Keeffe B; Shah A; Heller AH
    J Antimicrob Chemother; 1994 Jan; 33(1):111-8. PubMed ID: 8157551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In vitro antibacterial activity of ciprofloxacin against uropathogenic organisms].
    Allocati N; Catamo G; Cellini L
    Boll Soc Ital Biol Sper; 1984 Oct; 60(10):1927-33. PubMed ID: 6440583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetic and bactericidal characteristics of oral cefixime.
    Brittain DC; Scully BE; Hirose T; Neu HC
    Clin Pharmacol Ther; 1985 Nov; 38(5):590-4. PubMed ID: 4053491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [In vitro and in vivo antibacterial activities of pazufloxacin mesilate, a new injectable quinolone].
    Nomura N; Mitsuyama J; Furuta Y; Yamada H; Nakata M; Fukuda T; Yamada H; Takahata M; Minami S
    Jpn J Antibiot; 2002 Aug; 55(4):412-39. PubMed ID: 12378871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraprostatic concentration of ciprofloxacin and its activity against urinary pathogens.
    Hoogkamp-Korstanje JA; van Oort HJ; Schipper JJ; van der Wal T
    J Antimicrob Chemother; 1984 Dec; 14(6):641-5. PubMed ID: 6440885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers.
    Israel D; Gillum JG; Turik M; Harvey K; Ford J; Dalton H; Towle M; Echols R; Heller AH; Polk R
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2193-9. PubMed ID: 8257144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1994)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Matsuda M; Tanimoto H; Nakata K; Nakamori Y; Kusano N
    Jpn J Antibiot; 1996 May; 49(5):419-55. PubMed ID: 8752860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis.
    Goldfarb J; Wormser GP; Inchiosa MA; Guideri G; Diaz M; Gandhi R; Goltzman C; Mascia AV
    J Clin Pharmacol; 1986 Mar; 26(3):222-6. PubMed ID: 2937812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1989). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H
    Jpn J Antibiot; 1995 Sep; 48(9):1131-60. PubMed ID: 7474333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1992)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Tanimoto H; Nakata K; Nakamori Y; Nakatani T; Kusano N
    Jpn J Antibiot; 1996 Jan; 49(1):34-70. PubMed ID: 8851305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1993)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Tanimoto H; Nakata K; Nakamori Y; Nakatani T; Kusano N
    Jpn J Antibiot; 1996 Feb; 49(2):107-43. PubMed ID: 8721076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.